Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H16ClN3O4S2 |
| Molecular Weight | 389.878 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=NC(C)=C(S1)C2=CC(=C(Cl)C=C2)S(=O)(=O)NCCO
InChI
InChIKey=JFVNFXCESCXMBC-UHFFFAOYSA-N
InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16647110Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20510927
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16647110
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20510927
PIK-93 is the two most potent and multitargeted synthetic PI3-K inhibitors that have been reported. PIK-93 inhibits PI3Kγ and PI4KIIIβ, with IC50 values of 16 nM and 19 nM, respectively. PIK-93 also inhibits other members of PI3Ks, including PI3Kα, β, and δ, with IC50 values of 39 nM, 0.59 uM, and 0.12 uM, respectively. PIK-93 shows no obvious inhibitory effect against a panel of other kinases, even at a concentration of 10 uM. PIK-93 was identified as a potent anti-enterovirus compound. PIK-93 targeted PI4Kβ to inhibit interaction of viral 3D polymerase and phosphatidylinositol 4-phosphate on the reorganized membrane vesicle for viral replication complex formation. PIK-93 may provide a basis for the design of new classes of therapeutics against viral RNA replication.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4005 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16647110 |
39.0 nM [IC50] | ||
Target ID: CHEMBL3267 |
16.0 nM [IC50] | ||
Target ID: CHEMBL3142 |
64.0 nM [IC50] | ||
Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16647110 |
120.0 nM [IC50] | ||
Target ID: CHEMBL3268 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16647110 |
19.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells. | 2012-05-18 |
|
| Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. | 2010-05-28 |
|
| A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. | 2006-05-19 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22493444
In T6.11 cells, PIK-93 (300 nM) reduces carbachol-induced translocation of TRPC6 to the plasma membrane and net Ca2+ entry.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30425868
Created by
admin on Wed Apr 02 05:44:54 GMT 2025 , Edited by admin on Wed Apr 02 05:44:54 GMT 2025
|
PRIMARY | |||
|
593960-11-3
Created by
admin on Wed Apr 02 05:44:54 GMT 2025 , Edited by admin on Wed Apr 02 05:44:54 GMT 2025
|
PRIMARY | |||
|
6852167
Created by
admin on Wed Apr 02 05:44:54 GMT 2025 , Edited by admin on Wed Apr 02 05:44:54 GMT 2025
|
PRIMARY | |||
|
QS3XFL5JRX
Created by
admin on Wed Apr 02 05:44:54 GMT 2025 , Edited by admin on Wed Apr 02 05:44:54 GMT 2025
|
PRIMARY |